Float Short %

30.63

Margin Of Safety %

Put/Call OI Ratio

0.19

EPS Next Q Diff

-0.05

EPS Last/This Y

0.21

EPS This/Next Y

-0.26

Price

3.63

Target Price

18.44

Analyst Recom

1.6

Performance Q

-49.09

Relative Volume

0.31

Beta

0.07

Ticker: ALT

20 items of 1

Date	Symbol	Last	P/C OI	P/C Vol	Total OI
2025-08-15	ALT	3.62	0.26	0.20	191991
2025-08-18	ALT	3.55	0.26	0.16	180668
2025-08-19	ALT	3.6	0.25	0.21	184384
2025-08-20	ALT	3.62	0.25	0.39	187920
2025-08-21	ALT	3.53	0.25	0.21	190162
2025-08-22	ALT	3.54	0.25	0.17	190912
2025-08-25	ALT	3.39	0.25	0.33	189184
2025-08-26	ALT	3.43	0.25	0.63	190869
2025-08-27	ALT	3.66	0.24	0.24	191819
2025-08-28	ALT	3.7	0.24	0.23	197158
2025-08-29	ALT	3.82	0.24	0.28	202336
2025-09-02	ALT	3.75	0.21	1.02	197976
2025-09-03	ALT	3.67	0.22	0.74	201724
2025-09-04	ALT	3.55	0.22	0.58	203018
2025-09-05	ALT	3.78	0.22	0.33	203544
2025-09-08	ALT	3.7	0.18	0.39	198096
2025-09-09	ALT	3.78	0.19	0.15	199497
2025-09-10	ALT	3.67	0.19	0.31	201371
2025-09-11	ALT	3.68	0.19	0.31	203752
2025-09-12	ALT	3.63	0.19	0.14	204919
Date	Symbol	Last	P/C OI	P/C Vol	Total OI

20 items 1 of 1

20 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-08-15	ALT	3.62	8.4	-8.5	-1.12
2025-08-18	ALT	3.56	16.2	9.0	-1.12
2025-08-19	ALT	3.62	8.4	-15.7	-1.12
2025-08-20	ALT	3.62	8.4	-12.2	-1.12
2025-08-21	ALT	3.53	8.4	-5.9	-1.12
2025-08-22	ALT	3.53	16.2	-12.2	-1.12
2025-08-25	ALT	3.38	16.2	-2.2	-1.12
2025-08-26	ALT	3.44	16.2	-15.5	-1.12
2025-08-27	ALT	3.66	16.2	-26.1	-1.12
2025-08-28	ALT	3.71	16.2	-14.3	-1.12
2025-08-29	ALT	3.82	16.2	-18.4	-1.12
2025-09-02	ALT	3.75	16.2	-8.1	-1.13
2025-09-03	ALT	3.68	16.2	-75.3	-1.13
2025-09-04	ALT	3.55	16.2	-69.5	-1.13
2025-09-05	ALT	3.78	16.2	-105.0	-1.13
2025-09-08	ALT	3.71	16.2	-75.7	-1.13
2025-09-09	ALT	3.78	16.2	-88.8	-1.13
2025-09-10	ALT	3.67	16.2	-72.1	-1.13
2025-09-11	ALT	3.69	16.2	-83.6	-1.13
2025-09-12	ALT	3.63	16.2	-76.0	-1.13
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

20 items 1 of 1

20 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-08-15	ALT	1.20	-5.32	29.50
2025-08-18	ALT	1.20	-1.14	29.50
2025-08-19	ALT	1.20	-1.14	29.50
2025-08-20	ALT	1.20	-1.14	29.50
2025-08-21	ALT	1.20	-1.14	29.50
2025-08-22	ALT	1.20	-1.14	29.50
2025-08-25	ALT	1.20	-1.37	29.49
2025-08-26	ALT	1.21	-1.37	29.49
2025-08-27	ALT	1.21	-1.37	29.15
2025-08-28	ALT	1.21	-1.37	29.15
2025-08-29	ALT	1.21	-1.37	29.15
2025-09-02	ALT	1.21	-1.36	29.15
2025-09-03	ALT	1.29	-1.36	29.13
2025-09-04	ALT	1.29	-1.36	29.13
2025-09-05	ALT	1.29	-1.36	29.13
2025-09-08	ALT	1.29	-1.38	29.13
2025-09-09	ALT	1.29	-1.38	29.13
2025-09-10	ALT	1.29	-1.38	29.13
2025-09-11	ALT	1.29	-1.38	30.63
2025-09-12	ALT	1.29	-1.38	30.63
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

20 items 1 of 1

Last Quarter Act. EPS

-0.27

Avg. EPS Est. Current Quarter

-0.27

Avg. EPS Est. Next Quarter

-0.32

Insider Transactions

1.29

Institutional Transactions

-1.38

Beta

0.07

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

85.3

Max Drawdown 5-Year %

-91.2

Target Price

18.44

P/E

Forward P/E

PEG

P/S

16062.86

P/B

1.92

P/Free Cash Flow

EPS

-1.18

Average EPS Est. Cur. Y

-1.13

EPS Next Y. (Est.)

-1.4

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-438730

Relative Volume

0.31

Return on Equity vs Sector %

-79.2

Return on Equity vs Industry %

-66.1

EPS 1 7Days Diff

EPS 1 30Days Diff

0.1

EBIT Estimation

-76

Altimmune, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 59

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity, metabolic, and liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 trial for the treatment of obesity and metabolic associated steatohepatitis. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.

stock quote shares ALT – Altimmune, Inc. Stock Price stock today

news today ALT – Altimmune, Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch ALT – Altimmune, Inc. yahoo finance google finance

stock history ALT – Altimmune, Inc. invest stock market

stock prices ALT premarket after hours

ticker ALT fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: ALT

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Last Quarter Act. EPS

Average EPS Est. Cur. Y